Hyperaldosteronism Remission after Extended Aldosterone Synthase Inhibition
Among patients with hypertension due to primary aldosteronism, reductions in blood pressure and the aldosterone-to-renin ratio persisted for 2 years after completion of an extended course of aldosterone synthase inhibition.
Authors
- Ayşegül Eren
- Irina Bancos (ORCID: https://orcid.org/0000-0001-9332-2524)
- Oksana Hamidi (ORCID: https://orcid.org/0000-0002-7367-3885)
- Lawrence Steven Kirschner (ORCID: https://orcid.org/0000-0001-6180-342X)
- Mason Wright Freeman (ORCID: https://orcid.org/0000-0002-5254-9244)
- Anat Ben-Shlomo (ORCID: https://orcid.org/0000-0002-2912-5355)
- Adina F. Turcu (ORCID: https://orcid.org/0000-0001-9831-6190)
- Amir Hekmat Hamrahian (ORCID: https://orcid.org/0000-0001-8832-9385)
- Ramin Sam (ORCID: https://orcid.org/0000-0002-4016-6676)
- Morris Jonathan Brown (ORCID: https://orcid.org/0000-0001-8409-1082)
- Wenyu Huang (ORCID: https://orcid.org/0000-0002-7329-1887)
Institutions
- Northwestern University (US)
- Cedars-Sinai Medical Center (US)
- Mayo Clinic (US)
- Harvard University (US)
- Johns Hopkins University (US)
- Queen Mary University of London (GB)
- University of California, San Francisco (US)
- University of Michigan (US)
- The Ohio State University Wexner Medical Center (US)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- New England Journal of Medicine
- Published
- 2026-11-07
- DOI
- https://doi.org/10.1056/nejmc2611265
- Primary Topic
- Hormonal Regulation and Hypertension
- Type
- article
- Field-Weighted Citation Impact
- 0.00